Veliddin Canfeza SEZGİN, Bülent KARABULUT, Ulus Ali ŞANLI, Rüçhan USLU, Erdem GÖKER, Selahattin SANAL, Necmettin ÖZDEMİR

Meme kanserinde Kİ-67 ekspresyonu ve diğer prognostik faktörler ile ilişkisi

İnsan meme kanserlerinin klinik seyrinin çeşitli şekillerde ortaya çıktığı bilinmektedir. Geçmişte güvenilir ve tekrarlanabilir Prognostik göstergeleri tanımlamak için çok çaba harcanmıştır. Lenf nodu tutulumu, tümör derecesi ve tümör çapı en önemli prognostik faktörler olarak kabul edilir. Diğer önemli prognostik faktörler proliferatif aktivite, c-erbB-2 onkoprotein ekspresyonu, steroid reseptör durumu, p53 ekspresyonu ve hastanın yaşıdır. Hücre proliferasyonunun değerlendirilmesinde Ki-67 monoklonal antikorunun kullanılması, kolay ve güvenilir bir yöntem olarak gösterilmektedir. Ki-67 ekspresyonu ve diğer prognostik değişkenler arasındaki ilişki, primer meme kanserli 140 hastada araştırıldı. Bütün hastalarda Ki-67, östrojen reseptörü ve c-erbB-2 ekspresyonunu belirlemek için immunohistokimyasal yöntem kullanıldı. Ki-67, c-erbB-2 ve östrojen reseptör (ER) ekspresyonu, lenf nodu pozitifliği sırası ile % 64, % 71, %34ve% 74 bulundu. Ki-kare P değerleri; Ki-67, c-erbB-2 ve ER ekspresyonu arasında ilişki olduğunu gösterdi. Ki-67 ekspresyonu, lenf nodu durumu ve hastanın yaşı ile ilişkili değildi.

Anahtar Kelimeler:

Meme neoplazmları, Ki-67 antijeni, Reseptörler, östrojen, Genler, erbB-2, İmmünohistokimya

KI-67 expression in breast cancer and its relationship with other prognostic factors

Human breast carcinomas are known to exhibit a broad spectrum of clinical behavior. Many attempts have been made in the past to establish reliable and reproducible prognostic parameters. Lymph node involvement, tumor grading and tumor size are accepted as the most important prognostic factors. The proliferative activity, expression of c-erbB-2 oncoprotein, steroid receptors status, p53 expression and patient age are other important prognostic factors. The use of the monoclonal antibody Ki-67 represents an easy and reliable means of assesing cell proliferation. The association between Ki-67 immunoreactivity and other prognostic variables was invastigated in 140 patient with primary breast carcinomas, lmmunohistochemical procedure performed to determine Ki-67, estrogen receptor and c-erbB-2 expression in all cases. Ki-67, c-erbB-2 and estrogen receptor (ER) expression, lymph node positivity in the samples was % 64, % 71, % 34 and % 74, respectively. The chi-square P values are shown for the associations of Ki-67, c-erbB-2 and ER expression. The Ki-67 expression is not correlated with lymph node status and patient age.

Keywords:

Breast Neoplasms, Ki-67 Antigen, Receptors, Estrogen, Genes, erbB-2, Immunohistochemistry,

PDF

___

1. Fisher ER, Costantino J, Fisher B, et al. Pathologic finding from the National Surgical Adjuvant Breast Project (protocol 4): Discriminants for 15-year survival. Cancer 1993; 71: 2141-2150.
2. Rosen PP, Groshen S, Saigo PE, et al. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: A study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989; 7: 1239-1251.
3. Rosner D, Lane WW. Should all patients with node-negative breast cancer receive adjuvant therapy? Identifying additional subsets of low-risk patients who are highly curable by surgery alone. Cancer 1991; 68: 1482-1494.
4. Fisher ER, Redmond C, Fisher B, et al. Prognostic factors in NSABP studies of women with node-negative breast cancer. J Natl Cancer Inst Monogr 1992; 11: 151 -158.
5. McQuire WL, Tandon AK, Allred DC, et al. Treatment decisions in axillary node-negative breast cancer patients. J Natl Cancer Inst Monogr 1992; 11: 173-180.
6. Adami HO, Malker B, Holmbert L, et al. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986; 315:559-563.
7. Host H, Lund E. Age as a prognostic factor in breast cancer. Cancer 1986; 57: 2217-2221.
8. Harris AL, Nicholson S, Sainsburgy R, et al. Epidermal growth factor receptor and other oncogenes as prognostic markers. J Natl Cancer Inst Monogr 1992; 11: 181-187.
9. Foekens JA, van Putten WL, Prtengen H, et al. Prognostic value of PS2 and cathepsin-D in 710 human primary breast tumors: Multivariate analysis. J Clin Oncol 1993; 11: 899-908.
10. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200-206.
11. Dressier LG, Eudey L, Gray R, et al. Prognostic potential of DNA flow cytometry measurements in node-negative breast*cancer patients: Preliminary analysis of an intergroup study (INT-0076). J Natl Cancer Inst Monogr 1992; 11:167-172.
12. Nixon AJ, Neuberg D, et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 1994; 12: 888.
13. Albain KS, Allred KC, et al. Breast cancer outcome and predictors of outcome: are there age differentials? J1 Natl Cancer Inst Monogr 1994; 16: 35.
14. King C, Kraus M, Aaronson S. Amplification of a novel v-erbB-2 related gene in human mammary carcinoma. Science 1985; 229: 974-976.
15. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
16. Slamon D, Godolphin W, Jones L, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
17. Walker RA, Camplejohn RS. Comparison of monoclonal antibody Ki-67 reactivity with grade and DNA flow cytometry of breast carcinomas. Br J Cancer 1988; 57; 57: 281.
18. Brown RW, Allred DC, et al. Prognostic significance and clinical- pathological correlations of cell cycle kinetics measured by Ki-67 immunocytochemistry in axillary node- negative carcinoma of the breast. Breast Cancer Res Treat 1990; 16: 191.
19. Lelle RJ. In situ determination of the Ki-67 growth fraction ( Ki-67 ) in human tumors. Acta Histochem Suppl 1990; 39: 109-124.
20. Stumpp J, Dietl J, Geppert M. Growth fraction in breast carcinoma determined by Ki-67 immunostaining: correlation with pathological and clinical variables. Gynaecol Obstet Invest 1992; 33: 47-50.
21. Betta PG, Robutti F, Pilato FP, et al. Correlation of proliferation activity with pathological features in breast carcinoma. Eur J Gynaecol Oncol 1989; 10: 433-437.
22. Bouzubar N, Walker KJ, Griffiths K, et al. Ki-67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 1989; 59: 943-947.
23. Wrba F, Chott A, Reiner A, et al. Ki-67 immunoreactivity in breast carcinomas in relation to transferrin receptor expression, estrogen receptor status and morphological criteria. An immunohistochemical study. Oncology 1989; 46: 255-259.
24. Sahin AA, Ro JY, Block MB, et al. Ki-67 immunostaining in node-negative Stage l/ll breast carcinoma. Significant correlation with prognosis. Cancer 1991; 68: 549-557.
25. Veronese SM, Gambacorta M. Detection of Ki-67 proliferation rate in breast cancer. Correlation with clinical and pathologic features. Am J Clin Pathol 1991; 95: 30-34.
26. Campani D, De-Negri F, Fabri R, et al. Estrogen, progesterone receptors and proliferating activity evaluated by immunocytochemistry in breast cancer. Int J Biol Markers 1991; 6: 144-150.
27. Di-Stefano D, Mingazzini PL, Scucchi L, et al. A comparative study of histopathology, hormone receptors, peanut lectin binding, Ki-67 immunostaining, and nucieoiar organizer region-associated proteins in human breast cancer. Cancer 1991: 67; 463-471.
28. Lee AK, Wiley B, Loda M, et al. DNA ploidy, proliferation and neu-oncogene protein overexpression in breast carcinoma. Mod Pathol 1992; 5: 61-67.
29. Barbareschi M, Leonardi E, Mauri FA, et al. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlation with receptor status, proliferating markers, and clinical stage in human breast cancer. Am J Clin Pathol 1992;98:408-418.
30. Nicholson Rl, McClelland RA, Finlay P, et al. Relationship between EGF-R, c-erbB-2 protein expression and Ki-67 immunostaining in breast cancer and hormone sensitivity. Br J Cancer 1993; 29 A: 1018-1023.
31. Veronese SM, Gambacorta M, Gottardi O, et al. Proliferation index as a prognostic marker in breast cancer. Cancer 1993; 71: 3926-3931.
32. Trihia H, Murray S, Price K, et al. International Breast Cancer Study Group. Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors-a surrogate marker? Cancer 2003 Mar 1; 97 (5): 1321-31.
33. Dalquen P, Baschiera B, et al. MIB-1 (Ki-67) immunostaining of breast cancer cells in cytologic smears. Acta Cytol 1997 Mar- Apr; 41 (2): 229-237.
34. Ljung BM, Chew K, et al. Fine needle aspiration techniques for the characterization of breast cancers. Cancer 1994 Aug 1; 74 (3 suppl): 1000-1005.
35. Lee AK, Loda M, Mackarem G, et al. Lymph node negative invasive breast carcinoma 1 centimeter or less in size ( T1a,bN0M0 ): clinicopathologic features and outcome. Cancer 1997 Feb 15; 79 (4): 761-771.
36. Janicke F. Value of tumor biological prognostic factors in adjuvant therapy of node-negative breast cancer. Zentraibl Gynakol 1994; 116 (8): 449-455.
37. Chang J, Ormerod M, Powles TJ, et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000 Dec 1; 89 (11): 2145-52.
38. Colleoni M, Orvieto E, Nole F, et al. Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer 1999 Apr; 35(4): 574-9.
39. Oehler MK, Rehn M, et al. Correlation of the EGF-receptor with cell kinetic and classical prognostic factors in breast cancer. Anticancer Res 1997 Jul-Aug; 17 (4B): 3137-3140.
40. Klijn JG, Berns PM, Schmitz PI, et al. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992 Feb; 13 (1): 3-17.